Ascendis Pharma A/S Q4 2023 Earnings Report $140.28 -0.12 (-0.09%) As of 04:00 PM Eastern Earnings HistoryForecast Ascendis Pharma A/S EPS ResultsActual EPS-$1.66Consensus EPS -$2.15Beat/MissBeat by +$0.49One Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual Revenue$148.62 millionExpected Revenue$97.02 millionBeat/MissBeat by +$51.60 millionYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ4 2023Date2/7/2024TimeN/AConference Call ResourcesPress ReleaseASND Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Ascendis Pharma A/S Earnings HeadlinesAscendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6 at 8:30 AM | globenewswire.comAscendis Pharma Updates Articles for Financial FlexibilityDecember 31, 2024 | markets.businessinsider.comBuy this Stock before Trump Takes Office!We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. And it's not just because it hit a critical "buy now" price.January 6, 2025 | Behind the Markets (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)December 30, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)December 25, 2024 | markets.businessinsider.comAscendis Pharma A/S Announces U.S. Commercial Availability of YORVIPATH® for Hypoparathyroidism TreatmentDecember 19, 2024 | quiverquant.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
